Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Varadhan

Showing results (171-180 of 176) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 176 results.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Transplantation and Cellular Therapy|February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for MyelofibrosisTania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|May 23, 2018
Corrigendum to: Report: NIA Workshop on Measures of Physiologic Resiliencies in Human AgingEvan C Hadley, George A Kuchel, Anne B Newman, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Pageof 18

Showing results (171-180 of 176) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 176 results.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Transplantation and Cellular Therapy|February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for MyelofibrosisTania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|May 23, 2018
Corrigendum to: Report: NIA Workshop on Measures of Physiologic Resiliencies in Human AgingEvan C Hadley, George A Kuchel, Anne B Newman, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Pageof 18